All In Biotech

Drug Trial Radar · NCT06920069

Study of Concomitant Administration of the sIPV and DTaP or MMR

Phase IV Study of Evaluating Immunogenicity and Safety of Concomitant Administration of Sabin-strain-based Inactivated Poliovirus Vaccine (Vero Cells) and Adsorbed Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine or Measles, Mumps and Rubella Combined Live-attenuated Vaccine

Last checked: Nov 20, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 2,640 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

2,640

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

Jul 15, 2030

Study completion Jun 15, 2031

Sponsor

Sponsor type
Academic, hospital or other
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 2 months, up to 2 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, open-labeled phase IV clinical trial to evaluate the immunogenicity and safety of concomitant administration of sIPV and DTaP or MMR in infants aged 2 months. Primary immunogenicity endpoints in all groups include the seroconversion rate of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies 30 days after basic immunization. Secondary immunogenicity endpoints include the seropositive rates, seroconversion rates, geometric mean titer/concentration (GMT/GMC), geometric mean fold increase (GMFI) of type I, II, and III anti-poliovirus neutralizing antibodies, anti-DT, anti-TT, anti-PT, anti-FHA, and anti-PRN antibodies, and anti-measles, anti-mumps, and anti-rubella antibodies 30 days after full immunization. The secondary safety endpoints are the incidence of adverse events (AEs) within 30 minutes after each injection, the incidence of solicited local and systematic AEs in the period of solicitation after each injection, the incidence of unsolicited AEs in 30 days after each injection, the incidence of AEs in 30 days after each injection, and the incidence of serious adverse events in 6 months after administrations.

Conditions

  • Polio
  • Diphteria, Tetanus and Pertussis
  • MMR Vaccine

Interventions

  • sIPVBiological

    Sabin-strain-based inactivated vaccine (Vero cells), 0.5mL for each dose

  • DTaPBiological

    Adsorbed acellular pertussis, diphtheria and tetanus combined vaccine, 0.5mL for each dose

  • bOPV 1,3Biological

    Poliomyelitis Vaccine Type I Type Ⅲ in Dragee Candy (Human Diploid Cell), Live, 1g for each dose

  • MMR VaccineBiological

    Measles, Mumps and Rubella Combined Live-attenuated Vaccine, 0.5mL for each dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity index-seroconversion rate of type I anti-poliovirus neutrilizing antibodyTime frame: Between baseline and day 30 after basic vaccination
  2. Immunogenicity index-seroconversion rate of type II anti-poliovirus neutrilizing antibodyTime frame: Between baseline and day 30 after basic vaccination
  3. Immunogenicity index-seroconversion rate of type III anti-poliovirus neutrilizing antibodyTime frame: Between baseline and day 30 after basic vaccination
  4. Immunogenicity index-seroconversion rate of anti-DT antibodyTime frame: Between baseline and day 30 after basic vaccination
  5. Immunogenicity index-seroconversion rate of anti-TT antibodyTime frame: Between baseline and day 30 after basic vaccination
  6. Immunogenicity index-seroconversion rate of anti-PT antibodyTime frame: Between baseline and day 30 after basic vaccination
  7. Immunogenicity index-seroconversion rate of anti-FHA antibodyTime frame: Between baseline and day 30 after basic vaccination

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Lufeng Center for Disease Control and Prevenion

    Chuxiong, Yunnan, China

  • Yuanmou Center for Disease Control and Prevention

    Chuxiong, Yunnan, China

  • Wuding Center for Disease Control and Prevention

    Chuxiong, Yunnan, China

  • Yaoan Center for Disease Control and Prevention

    Chuxiong, Yunnan, China

  • Lancang Center for Disease Control and Prevention

    Puer, Yunnan, China

  • Yanshan Center for Disease Control and Prevention

    Wenshan, Yunnan, China

  • Qiubei Center for Disease Control and Prevention

    Wenshan, Yunnan, China

  • Guangnan Center for Disease Control and Prevention

    Wenshan, Yunnan, China

  • Mile Center for Disease Control and Prevention

    Yisa, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.